Premium
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus
Author(s) -
Van De Ree M. A.,
De Maat M. P. M.,
Kluft C.,
Meinders A. E.,
Princen H. M. G.,
Huisman M. V.
Publication year - 2003
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1046/j.1538-7836.2003.00357.x
Subject(s) - atorvastatin , medicine , fibrinogen , plasminogen activator , von willebrand factor , type 2 diabetes mellitus , diabetes mellitus , gastroenterology , dyslipidemia , hemostasis , fibrinolysis , placebo , endocrinology , disease , platelet , pathology , alternative medicine
Summary. Background : Patients with Type 2 diabetes mellitus have increased levels of hemostatic risk variables for cardiovascular disease, such as fibrinogen, von Willebrand factor (VWF), factor (F)VIIa, d ‐dimer and plasminogen activator inhibitor‐1 (PAI‐1). Objectives : To evaluate the effect of aggressive vs. standard dose atorvastatin on hemostatic cardiovascular risk factors in patients with Type 2 diabetes mellitus. Patients and methods : The effect of 30 weeks of treatment with atorvastatin 10 and 80 mg on hemostatic cardiovascular risk factors was assessed in a randomized double‐blind placebo‐controlled trial on 217 patients with Type 2 diabetes mellitus and dyslipidemia. Results and conclusions : Atorvastatin 10 and 80 mg dose‐dependently reduced d ‐dimer (7.4% and 8.5%, respectively, P for trend = 0.004) and PAI‐1 antigen levels (9.0% and 18%, respectively, P for trend = 0.021). Levels of fibrinogen, VWF, tissue‐type plasminogen activator and FVIIa were not influenced by atorvastatin. In conclusion, in patients with Type 2 diabetes mellitus, atorvastatin dose‐dependently improved the levels of the hemostatic risk variables d ‐dimer and PAI‐1.